

قيمة استخدام عقار الأمينوفيلين كعامل وقاية لعضلة القلب قبل اجراء عملية ترقيع الشرايين التاجية

رسالة مقدمة توطئة للحصول على درجة الدكتوراة
فى جراحة القلب و الصدر

مقدمة من

الطبيب/ محمد نبيل محمد عبد الجواد
بكالوريوس الطب و الجراحة-جامعة عين شمس
ماجستير الجراحة العامة-جامعة عين شمس

تحت إشراف

الأستاذ الدكتور/ عز الدين عبد الرحمن مصطفى

أستاذ و رئيس قسم جراحة القلب و الصدر
كلية الطب- جامعة عين شمس

الدكتور/ خالد محمد سمير

أستاذ مساعد جراحة القلب و الصدر
كلية الطب- جامعة عين شمس

الدكتور/ شريف عبد السميع أحمد منصور

مدرس جراحة القلب و الصدر
كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١٣

The Value of Preoperative Administration of Aminophylline as a Cardio Protective Agent During Coronary Artery Bypass Grafting

Submitted for the partial fulfillment of MD degree
In cardiothoracic surgery

By

Mohammed Nabil Mohammed Abd Al Jawad
M.B.B.Ch., MS (general surgery)-Ain Shams University

Under supervision of

Ezz El Din A. Mostafa, MD, PhD, MBA
Professor & HOD of Cardiovascular & Thoracic Surgery
Faculty of Medicine-Ain Shams University

Khaled M. Samir, MD
Assistant Professor of Cardiovascular & Thoracic Surgery
Faculty of Medicine-Ain Shams University

Sherif A.A. Mansour, MD
Lecturer of Cardiovascular & Thoracic Surgery
Faculty of Medicine-Ain Shams University

Faculty of Medicine
Ain Shams University
2013

Abstract

Objectives: Despite surgical and pharmacological advances in myocardial preservation during CABG, myocardial Ischemia Reperfusion damage remains the most uncontrolled aspect of cardiac operations. This study aims at evaluating the possibility that aminophylline could serve as a potential myocardial protector against reperfusion injury during coronary artery bypass grafting (CABG).

Methods: It is a prospective, randomized, single blinded, placebo - controlled study including two groups of patients. The sixty patients were randomly assigned by a random number generator to cases group (n=30) or control group (n=30). Aminophylline, 200 mg orally per day for 3 days, with a total dose of 600 mg was given to 30 patients (cases group), and placebo was given to the 30 others (control group). All patients underwent uniform pre/intra/post-operative management. All patients were followed up with Measurement of cardiac markers (Troponin I) and cardiac enzymes (CK-MB). Blood samples were collected before induction of anesthesia (T0), after 30 min of aortic cross clamping (ACC) (T1), and 1, 24, and 48 h postoperatively (T2, T3, T4). Measurement of preoperative concentration of aminophylline in serum. 12 lead ECG 48 hours postoperatively for any new Q waves or ST elevation or depression. Echocardiographic examination with full study and measurement of cardiac volume, function, and ventricular geometry at the 6th postoperative day.

Results: there were no hospital mortalities or perioperative MI's in either group. The total ICU stay hours and ventilation hours were significantly higher in the control group 67.20 ± 21.28 and 16.47 ± 8.76 hours respectively while in the case group they were 46.87 ± 14.46 and 12.20 ± 3.56 hours respectively with a p-value < 0.05 . The need of inotropes in the case group was lower than that in the control group in the immediate post by pass period. The need of inotropes in the case group again was lower than that in the control group in the ICU. Four patients needed the use of IABP equally in both groups. Measured enzyme levels in both groups were significantly higher than preoperative values all through the postoperative study period. These levels were less in the case group than those of the control throughout the entire measurement period. However, TnI and CK-MB levels in both groups were not significantly different with a p-value > 0.05 .

Conclusions: aminophylline may actually has some beneficial actions like decreasing the ventilation hours. The need of inotropic support and total ICU stay hours. However, the main objective and standard for its evaluation was cardiac enzymes Troponin I and CK-MB which both showed no significant difference between those on aminophylline and other patients not receiving the drug. Also, there was no correlation between aminophylline serum levels and those of cardiac enzymes.

Keywords: Aminophylline, ischemia-reperfusion injury, troponin, cardio pulmonary bypass, CABG.

Acknowledgements

First of all, the great thanks to Allah who enabled us to complete this work, hoping to provide a useful guide to the scope of myocardial protection.

I would like to express my deep gratitude and admiration to Professor Dr. **Ezz El Din A. Mostafa** , Professor & HOD of Cardiovascular & Thoracic Surgery , Ain Shams University, without his continuous guidance and encouragement this thesis would have never seen light.

I am just as much indebted to Professor Dr. **Khaled M. Samir, MD**, Assistant Professor of Cardiovascular & Thoracic Surgery, Ain Shams University, every step and every detail in this work have been kindly assisted and supported by his effort and his care.

A special measure of appreciation is extended for Dr. **Sherif A.A. Mansour, MD**, Lecturer of Cardiovascular & Thoracic Surgery, Ain Shams University. He offered me the utmost care, invaluable advice and unlimited support.

I also would like to thank all my professors, colleagues, doctors, nurses, lab technicians, administrative personnel and workers at the department of cardiovascular and thoracic surgery for their continuous support, care and help during my career, and I know no possible words would ever fulfill them their right.

I don't forget my family, my beloved wife and my little angel; the best helper for me, their full support, prayers and wishes was a great motive to accomplish this work. My deepest gratitude to them and thanks will never appreciate what I owe them.

To my lovely young daughter Mariam everything was by you and for you, you have been and will always remain my one true love. Sorry for being away so much .love you and adore you, sweetie.

List of Contents

Title	page
Introduction	1-2
Aim of the work	3
Review of literature :	
• Chapter 1 : Ischemia Reperfusion injury	4 - 20
• Chapter 2 : Myocardial Protection	21 - 24
• Chapter 3: Aminophylline as a Cardio Protective Agent	25 - 33
• Chapter 4: Cardiac markers	34 - 35
Patients and methods	36 - 41
Results	42 - 84
Discussion	85 - 96
Conclusion and Recommendations	97
Summary	98
References	99 - 104
Master Sheet	105 - 117
Arabic Summary	-----

List of Abbreviations

ACC: Aortic Cross Clamping

ACLS: Advanced Cardiac Life Support

ADP: Adenosine Diphosphate

APAF-1: Apoptosis-Activating Factor 1

ATP: Adenosine Triphosphate

Bad and Bax: Proapoptotic Proteins Bad and Bax

Bcl: B-Cell Cll/Lymphoma

Ca²⁺: Calcium Ion

CABG: Coronary Artery Bypass Grafting

cAMP: Cyclic Adenosine Monophosphate

CK: Creatine Kinase

CO: Cardiac Output

CPB: Cardiopulmonary Bypass

DNA: Deoxyribonucleic Acid

FITC: Fluorescein Isothiocyanate

GSH: Reduced Glutathione

GSSG: Oxidized Glutathione

IL-1: Interleukin-1

IL-6: Interleukin-6

I-R: Ischemia Reperfusion

LDH: Lactate Dehydrogenase

MDA: Malondialdehyde
MI: Myocardial Infarction
MPO: Myeloperoxidase
MPTP: Mitochondrial Permeability Transition Pore
NADP: Nicotinamide Adenine Dinucleotide Phosphate
NADPH: Nicotinamide Adenosine Dinucleotide Phosphate
Nfkb: Nuclear Factor Kappa B
NO: Nitric Oxide
NOS: Nitric Oxide Synthase
PARP: Poly (ADP)-Ribosylating
PKA: Protein Kinase A
PKC: Ca²-Dependent Protein Kinase
ROS: Reactive Oxygen Species
ROSC: Return of Spontaneous Circulation
SGOT: Serum Glutamic-Oxaloacetic Transaminase
SIR: Systemic Inflammatory Response
SIRS: Systemic Inflammatory Response Syndrome
SR: Sarcoplasmic Reticulum
TNF: Tumor Necrosis Factor
TnI: Troponin I
TnT: Troponin T
USA: United States of America

List of Figures

Fig No.	Title	Pg. No.
1	Putative major cascades of cardioprotection and phenotypes of protection,afforded by preconditioning or postconditioning , either by brief ischemia(s) or by pharmacological agents.	16
2	Ion exchange during reperfusion	17
3	Ion exchange during ischemia	17
4	Intracellular mechanisms regulate cardiomyocyte Ca ²⁺ homeostasis and reactive oxygen species formation, the two primary mediators of myocyte ischemia-reperfusion injury	18
5	Proposed mechanisms of cardiomyocyte apoptosis following ischemia-reperfusion injury.	19
6	Putative cascades of cell death due to ischemia reperfusion injury.	20
7	likely sequence of events in ischemia/reperfusion injury	33
8	Comparison between control and case groups in diseased vessels	56
9	Comparison between control and case groups in use of LIMA	58
10	Comparison between control and case groups in grafted vessels	60
11	Comparison between control and case groups in operation details	62
12	Comparison between control and case groups in ICU and ventilation hours	64

13	comparison between control and case groups in the need of inotropes in the immediate post bypass period and ICU period	66
14	EF by Echocardiography in both groups pre/post-operative period	72
15	Comparison between control and case groups in CK-MB	75,88
16	Comparison between control and case groups in Troponin I	76,77,89
17	Estimated marginal means of CK-MB in case group	78,90
18	Estimated marginal means of CK-MB in control group	79,91
19	Estimated marginal means of Troponin I in case group	80,92
20	Estimated marginal means of Troponin I in control group	81,93

List of Tables

Table No.	Title	Pg. No.
1	cardiac markers	35
2	Gender distribution in control and case groups	40
3	Comparison between control and case groups in age, weight,height and BMI	40
4	Smoking distribution in control and case groups	41
5	Smoking Duration in years in control and case groups	41
6	Comparison between control and case groups in DM	41
7	Comparison between control and case groups DM control, duration and complications	42
8	Comparison between control and case groups in Preop.co-morbidities	43
9	Comparison between control and case groups in Laboratory data at preoperative period	44
10	Comparison between control and case groups in Laboratory data at 24 hours post operatively	45
11	Comparison between control and case groups in Laboratory data before hospital discharge	46
12	Comparison between control group in Laboratory master sheet at different measurement times	47
13	Comparison between case group	48

	in Laboratory master sheet at different measurement times	
14	Comparison between control and case groups in pre vital data	49
15	Comparison between control and case groups in vital data during induction	49
16	Comparison between control and case groups in vital data immediate intraoperative after bypass	49
17	Comparison between control and case groups in vital data day 0	50
18	Comparison between control and case groups vital data after 24 hours	50
19	Comparison between control and case groups in vital data master after 48 hours	51
20	Comparison between control and case groups in vital data master before hospital discharge	51
21	Comparison between control groups in vital data at different measurement times	52
22	Comparison between Case groups in vital data at different measurement times	53
23	Comparison between control and case groups in number of diseased vessels	54
24	Comparison between control and case groups in Catheter	55

25	Comparison between control and case groups in final number of grafts	57
26	Comparison between control and case groups in conduit used	57
27	Comparison between control and case groups in targets	59
28	Comparison between control and case groups in operation details	61
29	Comparison between control and case groups in immediate intraoperative after bypass details	63
30	Comparison between control and case groups in ICU details	64
31	Comparison between control and case groups in ICU details	65
32	Comparison between control and case groups in preoperative echo 1	67
33	Comparison between control and case groups in preoperative echo 2	67
34	Comparison between control and case groups in postoperative echo 1	68
35	Comparison between control and case groups in postoperative echo 2	68
36	Comparison between preoperative echo and postoperative echo in control group	69
37	Comparison between preoperative echo and postoperative echo in case group	69
38	Comparison between preoperative echo and postoperative echo in control group	70
39	Comparison between preoperative echo and postoperative echo in case group	71
40	Comparison between control and case groups postop. complications	73

41	Comparison between pre and post comp in control and case group	73
42	Comparison between control and case groups in CK-MB	74,87
43	Comparison between control and case groups in Troponin I	76,80
44	Comparison between case group in CK-MB	78,90
45	Comparison between control group in CK-MB	79,91
46	Comparison between case group in Troponin I	80,92
47	Comparison between control group in Troponin I	81,93
48	Correlation between Aminophylin and TroponinI	82,94
49	Correlation between Aminophylin and CK-MB	82,94